Vitamin D analogue: potent antiproliferative effects on cancer cell lines and lack of hypercalcemic activity

Arch Pharm (Weinheim). 2015 May;348(5):315-29. doi: 10.1002/ardp.201400448. Epub 2015 Apr 10.

Abstract

The active form of vitamin D3, 1α,25(OH)2D3, plays a major role in maintaining calcium/phosphate homeostasis. In addition, it is a potent antiproliferative and pro-differentiating agent. Unfortunately, it usually causes hypercalcemia in vivo when effective antitumour doses are used. It has therefore been found necessary to synthesise new analogues that retain or even increase the antitumour effects but preclude hypercalcemia. This report presents the synthesis of a novel Gemini vitamin D analogue (UVB1) and its biological evaluation. We demonstrate that this compound has potent antitumoural effects over a wide panel of tumour cell lines while showing lack of hypercalcemic activity and toxicity effects in in vivo assays.

Keywords: Antiproliferative agents; Antitumour activity; Cancer treatment; Cell line; Gemini.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity
  • Calcium / blood
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Drug Design
  • Female
  • Humans
  • Hypercalcemia / blood
  • Hypercalcemia / chemically induced*
  • Inhibitory Concentration 50
  • Male
  • Mice
  • Mice, Nude
  • Molecular Structure
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Structure-Activity Relationship
  • Time Factors
  • Vitamin D / analogs & derivatives*
  • Vitamin D / chemical synthesis
  • Vitamin D / pharmacology*
  • Vitamin D / toxicity

Substances

  • Antineoplastic Agents
  • UVB1 compound
  • Vitamin D
  • Calcium